Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Neuroendocrine Tumors
Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome from the XERMELO Patient Registry
Read More
Neuroendocrine Tumors
A Population-Based Analysis of Risk for Cancer-Specific Death in Patients with NETs
Read More
Neuroendocrine Tumors
Multicenter Analysis of Treatment Outcomes for Well-Differentiated Grade 3 NETs
Read More
Neuroendocrine Tumors
Prognostic Factor Analysis in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms
Read More
Neuroendocrine Tumors
Pilot Study of XmAb18087, an SSTR2 × CD3 Bispecific Antibody, in Advanced NETs
Read More
Neuroendocrine Tumors
ATLANT Study Results of Lanreotide Autogel + Temozolomide Combination Therapy in Progressive Thoracic NETs
Read More
Neuroendocrine Tumors
Lanreotide as Maintenance Therapy After First-Line Treatment in Patients with Nonresectable Duodeno-Pancreatic NETs
Read More
Neuroendocrine Tumors
Comparative Analysis of Octreotide Long-Acting Release versus Lanreotide in Gastroenteropancreatic NETs
Read More
Neuroendocrine Tumors
The Use of Octreotide LAR in Routine Canadian Practice: Dosing Considerations and Persistence Rates
Read More
Neuroendocrine Tumors
177Lu-Octreotate-PRRT + Temozolomide/Capecitabine in Pancreas and Updated Midgut NETs
Read More
1
2
3
4
Page 2 of 4
Results 11 - 20 of 31